Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation

Phase 2

Completed

• Conditions: Ejaculation

• Registration Number: NCT00143117
• Lead Sponsor: Pfizer

Brief Summary

To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-08
• Primary Completion: 2005-06
• Study Completion: 2005-06
• Study First Submitted: 2005-08-30
• Study First Submitted QC: 2005-08-30
• Study First Posted: 2005-09-02
• Status Verified: 2012-11
• Last Update Submitted: 2012-11-05
• Last Update Posted: 2012-11-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 460

Inclusion Criteria

• Premature ejaculation as defined by DSM-IV

Exclusion Criteria

• History of erectile dysfunction

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Assessment of efficacy and safety

Secondary Outcome Measures

Name	Time	Method
Assessment of Quality of Sexual Life

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇺🇸 Milwaukee, Wisconsin, United States